Proportion and number of incident cancer deaths in coronary artery disease.
cancer-specific mortality
cardio-oncology
coronary artery disease
proportion
spectrum
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
17
07
2023
received:
28
02
2023
accepted:
15
09
2023
medline:
23
10
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Globally, coronary artery disease (CAD) and cancer are the leading causes of death. Studies focusing on the proportion and spectrum of cancer mortality among CAD patients are lacking. We aim to characterize the proportion and spectrum of cancer-specific mortality among patients with CAD. We analyzed 93,797 hospitalized survivors with angiographically documented CAD between 2007 and 2020 (mean age: 62.8 ± 11.1 years, 24.7% female) from Cardiorenal ImprovemeNt II (CIN-II) cohort. During the median follow-up of 4.8 years (IQR: 2.6-7.5), 13,162 (14.0%) patients died after discharge. A total of 1223/7703 (15.8% of cause-specific death) CAD patients died of cancer. The three most common types of cancer-specific death were lung (36.1%), liver (13.3%), and colorectum cancer (12.8%). Furthermore, male (adjusted HR 2.38, 95% CI: 1.99-2.85) and older (≥60 vs. <60 years, adjusted HR 3.25, 95%CI 2.72-3.88) patients had a significantly increased cancer-specific mortality. Our data suggest that nearly one-sixth of death is accounted for cancer among CAD patients within a median follow-up of 4.8 years. Lung, liver, and colorectum cancer are top three cancer-specific mortality. Further studies are needed to reduce cancer mortality for CAD patients, especially in older and male ones. (ClinicalTrials.gov NCT05050877).
Sections du résumé
BACKGROUND
Globally, coronary artery disease (CAD) and cancer are the leading causes of death. Studies focusing on the proportion and spectrum of cancer mortality among CAD patients are lacking. We aim to characterize the proportion and spectrum of cancer-specific mortality among patients with CAD.
METHODS
We analyzed 93,797 hospitalized survivors with angiographically documented CAD between 2007 and 2020 (mean age: 62.8 ± 11.1 years, 24.7% female) from Cardiorenal ImprovemeNt II (CIN-II) cohort.
RESULTS
During the median follow-up of 4.8 years (IQR: 2.6-7.5), 13,162 (14.0%) patients died after discharge. A total of 1223/7703 (15.8% of cause-specific death) CAD patients died of cancer. The three most common types of cancer-specific death were lung (36.1%), liver (13.3%), and colorectum cancer (12.8%). Furthermore, male (adjusted HR 2.38, 95% CI: 1.99-2.85) and older (≥60 vs. <60 years, adjusted HR 3.25, 95%CI 2.72-3.88) patients had a significantly increased cancer-specific mortality.
CONCLUSIONS
Our data suggest that nearly one-sixth of death is accounted for cancer among CAD patients within a median follow-up of 4.8 years. Lung, liver, and colorectum cancer are top three cancer-specific mortality. Further studies are needed to reduce cancer mortality for CAD patients, especially in older and male ones.
TRAIL REGISTRATION
(ClinicalTrials.gov NCT05050877).
Identifiants
pubmed: 37754571
doi: 10.1002/cam4.6595
pmc: PMC10587929
doi:
Banques de données
ClinicalTrials.gov
['NCT05050877']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20140-20149Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Eur Heart J Acute Cardiovasc Care. 2018 Oct;7(7):631-638
pubmed: 28593789
EClinicalMedicine. 2022 Apr 16;47:101384
pubmed: 35480076
Korean Circ J. 2021 Apr;51(4):336-348
pubmed: 33821583
Eur Heart J. 2016 Jan 21;37(4):412-22
pubmed: 26637834
Lipids. 1993 Aug;28(8):705-8
pubmed: 8377584
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biochem Biophys Res Commun. 1975 Oct 27;66(4):1173-9
pubmed: 2
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Circulation. 2018 Aug 14;138(7):727-734
pubmed: 30359131
J Breath Res. 2020 May 27;14(3):034001
pubmed: 32163929
J Am Coll Cardiol. 2020 Jun 2;75(21):2726-2737
pubmed: 32466889
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
Circulation. 2012 Aug 14;126(7):875-910
pubmed: 22800849
Eur Heart J. 2020 Jun 14;41(23):2194-2196
pubmed: 32068786
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Front Cardiovasc Med. 2022 Apr 29;9:878566
pubmed: 35571216
J Natl Cancer Inst. 2015 Nov 26;108(5):
pubmed: 26614095
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Transl Psychiatry. 2021 Oct 19;11(1):540
pubmed: 34667146
Annu Rev Med. 2018 Jan 29;69:97-111
pubmed: 29414258
J Geriatr Cardiol. 2020 Jan;17(1):1-8
pubmed: 32133031
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Cancer Med. 2023 Oct;12(19):20140-20149
pubmed: 37754571
JAMA Surg. 2016 May 1;151(5):441-50
pubmed: 26720406
Eur Heart J. 2020 Jun 14;41(23):2183-2193
pubmed: 31800032
Eur J Prev Cardiol. 2022 Mar 11;29(2):420-431
pubmed: 34922374
World Health Organ Tech Rep Ser. 1968;405:5-37
pubmed: 4975372
Circulation. 2014 Mar 25;129(12):1286-94
pubmed: 24515993
Heart. 2018 Oct;104(20):1647-1653
pubmed: 29764968
J Am Coll Cardiol. 2004 May 19;43(10):1731-7
pubmed: 15145091
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Int J Cancer. 2008 Jan 1;122(1):155-64
pubmed: 17893872
Eur Heart J. 2015 Oct 21;36(40):2696-705
pubmed: 26306399
Int J Mol Sci. 2014 Dec 24;16(1):193-217
pubmed: 25547488
BMJ. 2003 Feb 1;326(7383):256-7
pubmed: 12560277
Nat Rev Cancer. 2021 Dec;21(12):753-766
pubmed: 34417571
Ann Intern Med. 2016 Aug 2;165(3):161-6
pubmed: 27295519
Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005375
pubmed: 31163980
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Ann Rheum Dis. 2010 Feb;69(2):325-31
pubmed: 19773290
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Int J Epidemiol. 2012 Jun;41(3):861-70
pubmed: 22253319
Eur Heart J. 2019 Jun 7;40(22):1790-1800
pubmed: 30500952
Eur Heart J. 2016 Jan 21;37(4):378-85
pubmed: 26586780